MOTS-c

• Week 1-2: Users say effects build gradually over weeks
• Week 2-4: Some report more stamina (self-reports)
• Week 4-8: Some report body changes; store course ends week 6
• Week 8-12: 4-week break: judge if the changes hold up
• Side effects: 911: chest pain, allergy, racing heart not settling; see Side effects

More on each stage

Week 1-2

Community users say effects are gradual and take weeks to notice. Early on, watch for redness where you inject or trouble sleeping. In mice, daily shots improved insulin response within 7 days and running within 10 days (animal study).

Week 2-4

Some community users report more stamina on long days or in cardio sessions (self-reports). In a 4-week trial of a modified MOTS-c drug (CB4211, 25 mg a day), liver enzymes and blood sugar dropped in adults with obesity and fatty liver. That is a related but different drug.

Week 4-8

Some community users report body-composition changes. The store course ends after week 6.

Week 8-12

On the store plan you are in your 4-week break (weeks 7-10). Use it to judge whether the changes you felt hold up. Then you can start another 6-week course. Community guides repeat courses 2 to 4 times a year.

Side effects

Reported most often: redness or irritation where you inject, trouble sleeping, and a fast or pounding heartbeat. Stop and get help for swelling of the face or throat, trouble breathing, fever, or chest pain.

Based on what people report in the community sources below. Results vary, and many responses are anecdotal.

• Helps muscle use blood sugar

  Animal/lab study

  In mice on a high-fat diet, 7 days of daily MOTS-c shots improved insulin sensitivity by about 30% in a clamp test (the gold-standard insulin test), mostly by helping muscle take up sugar. It also undid the age-related drop in muscle sugar uptake in middle-aged mice.1

• Blocked diet-driven weight gain in mice

  Animal/lab study

  Mice on a high-fat diet that got daily MOTS-c shots for 8 weeks did not become obese, even though they ate the same amount. They also built up much less liver fat.1

• More running in old mice

  Animal/lab study

  Old mice (22 months) given daily MOTS-c shots for 2 weeks ran about twice as long and twice as far on a treadmill as untreated old mice. Old mice dosed 3 times a week had better grip strength and walking and less body fat.3

• Your body makes more when you exercise

  Human study

  In 10 healthy young men, a hard cycling session raised the body's own MOTS-c about 12-fold in muscle and about 1.5-fold in blood. Blood levels were back to normal 4 hours later. This is natural MOTS-c, not a shot.3

• A related drug lowered liver enzymes

  Clinical trial

  CB4211, a modified version of MOTS-c, was tested in 20 adults with obesity and fatty liver at 25 mg a day for 4 weeks. Liver enzymes fell (ALT 21%, AST 28%) and blood sugar fell 6%. These are company-reported results for a related molecule.5

• Stamina and energy

  Community report

  Community users mostly take MOTS-c around endurance exercise and say any effect is gradual, taking weeks to notice. These are self-reports.11

What it has been studied for

• Insulin resistance and diet-driven obesity (mice on a high-fat diet)1Animal/lab study
• Age-related loss of physical capacity and muscle function (old mice)3Animal/lab study
• How cells protect themselves under metabolic stress (cell studies)2Animal/lab study
• The body's own MOTS-c response to exercise (10 healthy young men)3Human study
• Fatty liver and obesity with CB4211, a modified MOTS-c drug (20 adults, 4 weeks; company-reported results)5Clinical trial
• Heart protection, inflammation, and pain (mostly animal studies, summarized in a review)4Animal/lab study

MOTS-c is a peptide 16 building blocks (amino acids) long. Its recipe comes from the DNA inside your mitochondria, the tiny power plants in each cell. Its main target seems to be muscle. In cells and mice, it slows one of the cell's chemical production lines. That lets a natural compound build up, which switches on the cell's fuel sensor. The fuel sensor tells muscle to take in and burn more sugar. Under stress, MOTS-c can also move into the cell's control centre (the nucleus) and switch on genes that protect the cell from damage. All of this comes from cell and animal studies.

Peak

Not established in humans. The FDA says it has no human exposure data for MOTS-c. The discovery study gave it to mice into the belly cavity and did not report blood levels after a shot.

Half-life

Not established in humans. A community review of the research found no published measurement in animals either. It is a short peptide with no protective changes, so it is expected to break down fast, but no number has been measured. Treat any half-life figure you see online with caution.

Cleared

Not established. For comparison only: the body's own MOTS-c rose in the blood during hard exercise and was back to normal 4 hours later. That is natural MOTS-c, not an injected dose.

Half-life is how long it takes the body to remove half of a dose.61312

Twice a week. Morning (store protocol). Many community users time the shot before a workout. Avoid evening shots: trouble sleeping has been reported. 2 days a week, 3 to 4 days apart (for example Monday and Thursday). Units are for a 40 mg vial mixed with 1 mL water (40 mg per mL).

• Lower end · single pre-endurance shot

  10 mg once weekly before exercise

  A single weekly injection some use before endurance work, aiming for added mitochondrial signaling.11

• Most common · standard exercise-mimetic dose

  5-10 mg, 2-3 times weekly

  The standard community dose, split across the week and frequently timed before endurance exercise — framed as an 'exercise mimetic,' not a replacement for training.11

• Standard protocol (most popular)

  5-10 mg under the skin, 2 to 3 times a week, often timed around exercise, for 4 to 10 weeks.11

• Single weekly shot

  10 mg once a week before endurance exercise, for up to 10 weeks.11

• Daily low dose

  1 mg once a day for 4 to 8 weeks.11

• Course length

  4-6 week courses with rest between them, repeated 2 to 4 times a year. Morning or before exercise.12

Research protocols

• Mice on a high-fat diet (obesity study)

  0.5 mg per kg of body weight once a day, injected into the belly cavity, for 8 weeks.1

• Mice on a high-fat diet, and middle-aged mice (insulin study)

  5 mg per kg once a day, injected into the belly cavity, for 7 days.1

• Old mice (exercise study)

  15 mg per kg once a day for 2 weeks, injected into the belly cavity. A late-life group got 15 mg per kg 3 times a week.3

• Human trial of CB4211, a modified MOTS-c drug (adults with obesity and fatty liver)

  25 mg under the skin once a day for 4 weeks. CB4211 is a different molecule from the MOTS-c in this vial.5

MOTS-c has never been tested in human clinical trials — every protocol is extrapolated from mouse data. It is WADA-prohibited for sport. The 'exercise replacement' framing is misleading; it activates similar pathways to exercise but cannot replicate them.

Dosing guidance built from the cited research and community reports. It is not a prescription.

1. 1
2. 2
3. 3
4. 4
5. 5
6. 6
7. 7
8. 8
9. 9
10. 10

On: 6 weeks Break: 4 weeks

A full course at the store pace takes 1 vial. A mixed vial keeps for up to 90 days.

Why the break helps

Community guides also run short courses with rests between them, 2 to 4 times a year. The FDA says it has no human exposure data for MOTS-c and lists a possible immune-reaction risk, so a break limits how long you are exposed. It also lets you judge whether the changes you felt hold up without it.

Common

• Redness, irritation, or itching where you injected. This was the most common side effect of the modified MOTS-c drug in its human trial, and people using MOTS-c report it too.

  What to do Rotate spots and use a fresh syringe every time. If redness spreads or gets hot and painful, treat it as an infection (see below).

• Trouble sleeping (reported by users, especially at higher amounts)

  What to do Take your shot in the morning. If it continues, go back to the store dose of 2.5 mg (the 6.5-unit mark) or stop.

• Fast or pounding heartbeat (palpitations), reported by people who bought MOTS-c online

  What to do Skip your next dose and rest. If it keeps happening, stop MOTS-c and tell a doctor. If you have chest pain or feel faint, see the serious list.

• Nausea or stomach discomfort (community reports)

  What to do Eat a light meal and drink water. If it lasts more than a day or two, lower the dose or stop.

• Shaky, sweaty, hungry, or light-headed. MOTS-c is expected to lower blood sugar, though low blood sugar was not reported in mouse studies. The risk is higher if you are fasting or take diabetes medicine.

  What to do Eat or drink something with sugar right away and check your blood sugar if you can. Do not inject on a long fast. Talk to your doctor if you take diabetes medicine.

Stop and get help

• Allergic reaction: hives, swelling of the face or throat, trouble breathing, or feeling faint. The FDA flagged a possible immune-reaction risk for MOTS-c.

  What to do Stop MOTS-c and call 911 (or your local emergency number) right away.

• Fever or a body-wide immune reaction (reported by people who bought MOTS-c online)

  What to do Stop MOTS-c and see a doctor promptly. Bring the vial so they know what you took.

• Chest pain, a racing heartbeat that will not settle, or fainting

  What to do Stop MOTS-c and call 911 (or your local emergency number).

• Severe low blood sugar: confusion, slurred speech, or passing out, most likely if you take insulin or other diabetes medicine

  What to do Call 911. If the person is awake and can swallow, give them sugar while you wait.

• Infection at the injection site: redness that spreads, heat, pus, red streaks, or fever

  What to do Stop injecting and see a doctor the same day.

Do not use if

• You are pregnant, trying to get pregnant, or breastfeeding: there is no safety data.
• You are under 18: there is no data in children or teens.
• You have active cancer: listed as a precaution in community safety guides. There is no data either way.
• You take insulin or other diabetes medicine, unless your doctor agrees and you check your blood sugar.
• You take methotrexate or another folate-blocking drug, or you are low in folate: MOTS-c also slows the folate cycle.
• You compete in a drug-tested sport: WADA bans MOTS-c at all times, and USADA says a medical exemption is highly unlikely.

Sources613

Storage

Keep it

Keep the mixed vial in the fridge (2-8 °C / 36-46 °F), upright and away from light. Do not freeze it, and never leave it in a hot car.

How long

Use within 90 days of mixing. A mixed vial kept in the fridge holds its strength for 60-90 days, then slowly starts to lose potency. Wipe the rubber top with an alcohol swab before every draw.

Drawing your dose

Syringe: a 0.3 mL (30-unit) U-100 insulin syringe with half-unit marks, so small doses are easy to read.

1. With this mix, each 1 unit line on a U-100 insulin syringe holds 0.4 mg (400 mcg). The 2.5 mg store dose falls between lines: draw to the 6.5-unit mark (2.6 mg). Draw 12.5 units for 5 mg, or 25 units for 10 mg.
2. The last draw can come up a little short, because a few drops stay in the vial; tilt the vial and pull from the lowest point.
3. Check the liquid before each dose. It should be clear. Do not use it if it looks cloudy or has specks.
4. Wipe the top before every draw. Hold the syringe at eye level, flick out air bubbles, and push the plunger back to the exact line.
5. Pinch a fold of skin, insert the needle at 45 to 90 degrees, push slowly, and wait a few seconds before pulling out. Use a new sterile syringe every time and never share one.

• SS-31

  They work on mitochondria from different angles. MOTS-c acts as a signal that switches on the AMPK fuel sensor. SS-31 sits on the inner membrane of the mitochondria, where it supports energy production and cuts damaging by-products; in old mice it reversed age-related heart stiffness. A community protocol site lists MOTS-c + SS-31 as a "mitochondrial stack" (AMPK signaling plus cardiolipin support). The pair has not been tested together.911

• CJC-1295 No DAC / Ipamorelin

  Different jobs: CJC-1295 and Ipamorelin are growth-hormone releasers (secretagogues), while MOTS-c targets how muscle uses fuel. A community protocol site lists a MOTS-c + CJC-1295/Ipamorelin "metabolic stack" for body composition and recovery. The pair has not been tested together.11

• NAD+

  NAD+ is a central molecule in how cells make energy, and levels may be 10-80% lower with age in people. NAD+ supports the energy machinery itself, while MOTS-c acts as a signal sent from mitochondria. A wellness video groups MOTS-c, NAD+, and SS-31 as peptides for mitochondrial health. The pair has not been tested together.1014

Interactions

• Insulin, sulfonylureas (such as glipizide), and other medicines that lower blood sugar

  MOTS-c is expected to lower blood sugar, so lows could add up. This has not been studied.

  What to do Ask your doctor first and check your blood sugar more often, especially in the first weeks.

• Metformin or other AMPK activators

  They switch on the same fuel sensor, so the effects may add up. This has not been studied.

  What to do Tell your doctor before combining them and watch for signs of low blood sugar.

• Methotrexate, pemetrexed, and other folate-blocking drugs

  MOTS-c also slows the folate cycle, so it could add to these drugs' side effects. This has not been studied.

  What to do Do not use MOTS-c during this treatment unless your doctor agrees.

• Folate or folic acid supplements

  Extra folate might blunt MOTS-c's effect. This is a theory, not a safety risk.

  What to do No change needed. Do not stop a folate supplement your doctor prescribed.

Videos

• The BEST Peptides for Mitochondrial Health (MOTS-c, NAD+, SS-31 Explained)Dr. Jones, DC · 2026
• The "Battery Peptides"? | MOTS-c & SS-31 Explained SimplyDenver Regenerative Medicine · 2026

Sources

1. 1Lee et al., Cell Metab 2015 (discovery of MOTS-c; mouse obesity and insulin studies)Study
2. 2Kim et al., Cell Metab 2018 (MOTS-c moves to the nucleus under stress; cell studies)Study
3. 3Reynolds et al., Nat Commun 2021 (exercise raises MOTS-c in people; old-mouse performance)Study
4. 4Zheng et al., Front Endocrinol 2023 (MOTS-c review)Review
5. 5PatientWorthy 2021: CohBar CB4211 (modified MOTS-c) phase 1a/1b topline results, company-reportedReference
6. 6FDA: Bulk drug substances that may present significant safety risks (MOTs-C entry: no human exposure data, immunogenicity risk)Reference
7. 7USADA: What is the MOTS-c peptide? (prohibited at all times; reported side effects)Reference
8. 8German Sport University Cologne: WADA 2026 Prohibited List, class S4 (names MOTS-c as an AMPK activator)Reference
9. 9Chiao et al., eLife 2020 (SS-31 restores mitochondrial and heart function in old mice)Study
10. 10Freeberg et al., J Gerontol A 2023 (NAD+ in humans review)Review
11. 11Peptide Protocol Wiki: MOTS-c community protocols (40 reports)Community
12. 12Peptide Protocol Wiki: MOTS-c dosing, mixing, and storageCommunity
13. 13Peptide Protocol Wiki: MOTS-c side effects and interactionsCommunity
14. 14Dr. Jones, DC (YouTube): The BEST Peptides for Mitochondrial Health (MOTS-c, NAD+, SS-31 Explained)Video

Where people discuss it

• r/Peptides (subreddit)
• Peptide Protocol Wiki — MOTS-c community (40 reports)

Some peptides, like semaglutide (Ozempic and Wegovy), are FDA-approved medicines. Most of the peptides people research are not. That label sounds like the FDA tested something and turned it down. Usually it means something else: nobody has paid for the studies the FDA needs to see. Here is why.

The FDA doesn’t test drugs. Companies do.

The FDA does not run its own drug tests. A company that wants to sell a new medicine has to test it first, and pay for it. It studies the drug in animals, then in people: first 20 to 100 volunteers, then a few hundred, then up to 3,000. Then it sends all the results to the FDA. FDA scientists review them and decide whether the benefits outweigh the risks.

So approval always starts with a company asking for it. If no company applies, the FDA has nothing to review, however promising the research looks.

Those studies cost about a billion dollars

A study in the medical journal JAMA estimated that bringing one new drug to market costs a typical company about $1.1 billion. That figure includes the money spent on drug ideas that failed along the way, because many drugs that start human testing never make it.

A patent is how a company earns that money back

A patent is a right the government gives an inventor. For up to 20 years from the day the inventor applies, nobody else may make or sell the invention without permission.

For a drug company, that right is what makes the billion-dollar bet worth it. While the patent lasts, the company is the only seller, so it can charge enough to pay back the studies and the failures. When the patent runs out, other companies can sell cheap copies, called generics, and the price drops.

The FDA adds a shorter shield of its own. For 5 years after a brand-new drug is approved, no copycat version can apply for approval. That helps, but it is much shorter than a patent can last.

Why most peptides can’t be patented

To get a patent, an invention has to be new, and it has to be something people made, not something found in nature. Most popular peptides fail one test or both.

They come from nature. Many are copies or small pieces of molecules your body already makes. KPV is a 3-building-block piece of the hormone that tans your skin. BPC-157 is copied from a protein in stomach juice. In 2013 the US Supreme Court ruled that something that exists in nature, like a human gene, cannot be patented just because someone found it and pulled it out.

They aren’t new anymore. Many were first described in research papers decades ago. Scientists were already testing KPV in the 1980s. Once something has been published, it no longer counts as new, so nobody can patent it now, and any patents from back then have long since run out.

Without a patent, a company that paid for the studies would soon face rivals selling the same peptide without having paid for any research. Few companies will spend a billion dollars on a product anyone can copy. So nobody goes first, and the large human studies never happen.

The workaround: change the molecule

Drug companies do make peptide medicines, but they change the peptide first. A changed molecule is a new invention, so it can be patented. Semaglutide is a lab-made version of GLP-1, a gut hormone your body releases after meals, changed so one shot lasts a week. Tesamorelin (Egrifta) is the body’s own growth-hormone signal with a small fatty chain added. Both went through the full studies, and both are FDA-approved.

The natural versions, and the many peptides nobody has changed and patented, stay where they are: studied in labs and animals, used by the biohacking community, and never put through large human trials.

What this means for you

When a peptide is “not FDA-approved,” it usually means no company has paid for the large human studies. It does not mean the FDA tested it and found it harmful.

It also does not mean it is proven safe or proven to work. Without those studies, nobody knows the best dose for sure, or what rare or long-term side effects it may have. And the FDA does not check research peptides for purity or strength the way it checks approved medicines. That is why this page labels every finding by the kind of study behind it, and lists who should not use it.

Sources for this section

1. 1FDA: How drugs are developed and approved (the FDA does not test drugs; companies submit the evidence)
2. 2FDA: The drug development process, step 3: clinical research (study sizes for each phase)
3. 3Wouters, McKee & Luyten, JAMA 2020, corrected 2022: median cost to bring a new drug to market, $1.14 billion
4. 4US patent law, 35 U.S.C. § 154: a patent lasts 20 years from the filing date
5. 5FDA: Frequently asked questions on patents and exclusivity (5-year new chemical entity exclusivity)
6. 6US Supreme Court, Association for Molecular Pathology v. Myriad Genetics (2013): naturally occurring genes cannot be patented